PTC Therapeutics, Inc. provided revenue guidance for the full year 2018. For the year, the company anticipates revenues to be between $260 and $295 million. The company anticipates Translarna net product revenue to be between $170 and $185 million. The company anticipates EMFLAZA net product revenue to be between $90 and $110 million.